QuidelOrtho Corporation (NASDAQ:QDEL) Receives $12.38 Consensus PT from Brokerages

Shares of QuidelOrtho Corporation (NASDAQ:QDEL) have earned an average recommendation of “Reduce” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $13.6250.

QDEL has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Jefferies Financial Group reiterated a “hold” rating on shares of QuidelOrtho in a research report on Monday, June 29th. Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. Citigroup upped their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, UBS Group reiterated a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a report on Thursday, May 7th.

Hedge Funds Weigh In On QuidelOrtho

Large investors have recently bought and sold shares of the stock. Aristotle Capital Boston LLC raised its holdings in QuidelOrtho by 62.4% during the 3rd quarter. Aristotle Capital Boston LLC now owns 382,389 shares of the company’s stock valued at $11,261,000 after buying an additional 146,956 shares during the last quarter. Tejara Capital Ltd boosted its holdings in shares of QuidelOrtho by 97.2% during the fourth quarter. Tejara Capital Ltd now owns 208,327 shares of the company’s stock worth $5,950,000 after purchasing an additional 102,700 shares during the period. Phocas Financial Corp. boosted its holdings in shares of QuidelOrtho by 45.7% during the fourth quarter. Phocas Financial Corp. now owns 170,018 shares of the company’s stock worth $4,856,000 after purchasing an additional 53,353 shares during the period. Rice Hall James & Associates LLC grew its stake in shares of QuidelOrtho by 222.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 833,791 shares of the company’s stock worth $23,813,000 after purchasing an additional 574,877 shares during the last quarter. Finally, Monaco Asset Management SAM grew its stake in shares of QuidelOrtho by 131.0% in the fourth quarter. Monaco Asset Management SAM now owns 202,595 shares of the company’s stock worth $5,786,000 after purchasing an additional 114,895 shares during the last quarter. 99.00% of the stock is owned by hedge funds and other institutional investors.

QuidelOrtho Price Performance

Shares of QuidelOrtho stock traded up $0.83 during trading on Friday, hitting $18.27. 1,278,421 shares of the stock traded hands, compared to its average volume of 1,612,494. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -1.03 and a beta of 0.69. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33. QuidelOrtho has a 52 week low of $9.92 and a 52 week high of $35.58. The firm’s fifty day moving average is $13.65 and its 200-day moving average is $19.55.

QuidelOrtho (NASDAQ:QDEL) last released its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The firm had revenue of $619.80 million during the quarter, compared to the consensus estimate of $665.23 million. During the same quarter in the previous year, the firm earned $0.74 EPS. The business’s quarterly revenue was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Research analysts expect that QuidelOrtho will post 1.87 EPS for the current fiscal year.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.